Skip to main content
ConductScienceScienceDex

Kexin Xu

NIH Rank #17425
Unclaimed recordClaim profile
  • R01 Holder
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 10424828Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2026Career claims are limited to the years shown.

FY2026 award categories

  • Public Health

NIH Funding · FY2025

Linked Award Amount
$948.9K
Full award amounts, FY2025
Award Records
3
Records listing this PI
Award-Linked Rank
#17,425
By linked amount among FY2025 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Kexin Xu. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2025 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2025 award records by amount

NIH award records listing Kexin Xu as a PI. Multi-PI records show the full award amount for context.

  • 7R01CA279681-02R01
    Function of the METTL3-NUP93 complex-mediated nuclear export of m6A-modified mRNAs in castration-resistant prostate cancer.
    University of Virginia
    $413K
    award amount
  • 5R01GM140084-06R01
    METTL3-NUP93 interaction facilitates the nuclear export of m6A-modified mRNAs
    University of Virginia
    $347.2K
    award amount
  • 5R21CA277399-03R21
    Development of a new class of EZH2 inhibitors in ERa-negative breast cancer
    University of Virginia
    $188.8K
    award amount

Award organization

Organizations that administered FY2025 awards listing Kexin Xu as a PI.

FY2025 award administered by University of Virginia (VA).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    University of Virginia
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2025
    R01 Grant Holder
  5. 2026
    $2M Cumulative Funding

Explore further

Find collaborators for Kexin Xu

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →